Guidance on qualified person responsible for pharmacovigilance (QPPV) including pharmacovigilance system master files (PSMF)

The following legal obligations apply to holders of UK marketing authorisations (MA). These include those that cover the whole of the UK, or are specific to Northern Ireland or to Great Britain (England, Wales and Scotland), including Great Britain MAs granted to allow unfettered access from Northern Ireland.

• To operate a pharmacovigilance system for UK authorised products
• To have an appropriately qualified person responsible for pharmacovigilance (QPPV) that resides and operates anywhere in the UK or in the EU/EEA and is responsible for the establishment and maintenance of the pharmacovigilance system for UK authorised products
• To maintain and make available upon request a pharmacovigilance system master file (PSMF) that describes the pharmacovigilance system for UK authorised products. The PSMF must be accessible electronically from the UK at the same site at which reports of suspected adverse reactions may be accessed

Guidance on the QPPV for UK authorised products

For all UK MAs, including those that cover the whole of the UK or are specific to Northern Ireland or to Great Britain, the marketing authorisation holder (MAH) must have permanently and continuously at its disposal a QPPV who resides and operates anywhere in the UK or in the EU/EEA, and is responsible for the establishment and maintenance of the pharmacovigilance system (“the UK QPPV”). Where the QPPV is not in the UK, there will be a need for a national contact person for pharmacovigilance as set out below.

This is provided for by regulation 182 of the Human Medicines Regulations 2012 (as amended) (HMR).

For MAs that cover the whole of the UK or are specific to Northern Ireland, the legal requirements concerning the qualifications and responsibilities of the QPPV that are outlined in Article 10 of the Commission Implementing Regulation (EU) No 520/2012 (CIR) will remain unchanged.

For MAs that are specific to Great Britain, legal requirements concerning the qualifications and responsibilities of the QPPV are outlined in paragraph 10 of HMR Schedule 12A (inserted by the EU Exit Regulations 2019), which mirrors Article 10 of CIR.

Statutory guidance concerning the QPPV for UK authorised products is described in the Good Pharmacovigilance Practices (GVP) Module I. This guidance is supplemented by the Exceptions and modifications to the EU guidance on good pharmacovigilance practices that apply to UK marketing authorisation holders.

There is no temporary exemption as to the requirement to have a QPPV who resides and operates in the UK or the EU/EEA and is responsible for the pharmacovigilance system for UK authorised products.

National contact person for pharmacovigilance

If you choose to establish a QPPV who resides and operates in the EU/EEA, you must nominate a national contact person for pharmacovigilance who resides and operates in the UK and reports to the QPPV. This individual should have access to the reports of suspected adverse reactions referred to in regulation 187 of the HMRs and the PSMF for UK authorised products. The individual should be able to facilitate responses to pharmacovigilance queries raised by the MHRA, including via inspections.

There will be a temporary exemption in place which allows you 12 months from 1 January 2021 to appoint a national contact person for pharmacovigilance that resides and operates in the UK.

Once the national contact person for pharmacovigilance has been appointed, their details should be notified to the MHRA via the MHRA Submissions Portal. You should follow the instructions for submitting these details. You should receive a confirmation by email immediately upon completion of the form.

There is no requirement to appoint a deputy for the UK national contact person for pharmacovigilance, but for periods of extended absence greater than one month (such as maternity leave, long-term sick leave, etc.), it is expected that another individual is assigned as the national contact person for pharmacovigilance and their details should be notified to the MHRA within two weeks of the change. In practice, this means editing the existing details of the national contact person for pharmacovigilance that are saved in the MHRA Submissions portal.

Guidance on the PSMF for UK authorised products

For all UK national MAs, including those that cover the whole of the UK or are specific to Northern Ireland or to Great Britain, the MAH must maintain, and make available upon request of the MHRA, a PSMF that describes the pharmacovigilance system for UK authorised products (‘the UK PSMF’).

PSMF accessibility in the UK

All UK PSMFs must be accessible electronically at the same point in the UK from which the reports of suspected adverse reactions referred to in regulation 187 of the HMRs are accessible. This requirement applies from 1 January 2021.

The PSMF needs to be permanently and immediately available for inspection at the stated location in the UK.

PSMF format, content and representation of pharmacovigilance systems

For MAs that cover the whole of the UK or are specific to Northern Ireland, the legal requirements concerning the format and content of the PSMF that are outlined in Chapter I of CIR will remain unchanged.

For MAs that are specific to Great Britain, legal requirements concerning the format and content of the PSMF are outlined in Part 1 of Schedule 12A of HMR, which mirrors Chapter I of CIR.

As the legal requirements concerning PSMF format and content are identical for MAs that cover the whole of the UK and Northern Ireland, and those that are specific to Great Britain, a single UK PSMF can be used for all UK authorised products. This is assuming that the pharmacovigilance system applied to all products is the same.

Statutory guidance concerning the PSMF for UK authorised products is described in GVP Module II. This guidance is supplemented by the Exceptions and modifications to the EU guidance on good pharmacovigilance practices that apply to UK marketing authorisation holders.

The UK PSMF must describe the global pharmacovigilance system and reflect the global availability of safety information for UK authorised products.

As per GVP Module II, there are different approaches to establishing a pharmacovigilance system. For example:

• MAHs can establish more than one pharmacovigilance system
• A pharmacovigilance system can be shared by several MAHs

The UK PSMF should be an accurate representation of the pharmacovigilance system that has been established and you must make sure that every pharmacovigilance system covering UK authorised products has been assigned a unique PSMF number by the MHRA.

How to request a UK PSMF number

All PSMFs that cover UK authorised products should be registered with the MHRA. You should request a unique UK PSMF number from the MHRA for each pharmacovigilance system that you are operating for UK authorised products. Where the pharmacovigilance system is shared by several MAHs, a single request for a UK PSMF number should be submitted to the MHRA.

A UK PSMF number can be requested via the MHRA Submissions Portal. You should follow the online instructions for requesting a UK PSMF number and you should receive the number by email immediately upon completion of the form. The address from which the PSMF can be electronically accessed must be in the UK. Your UK PSMF number will be invalidated if the address provided is not in the UK. Any submissions to the MHRA using an invalidated UK PSMF number will not be accepted.

The UK PSMF number will be sent to the UK QPPV email address as well as the email address you nominated on the UK PSMF number request form. If you have not received a confirmation email within three hours of submitting the form, please contact submissions@mhra.gov.uk. Please do not re-submit the form as this will cause delays in processing your request.

Once a UK PSMF number is assigned to a pharmacovigilance system it should remain unchanged, irrespective of how the system may change and evolve over time. You should not request a new UK PSMF number if there are changes to the pharmacovigilance system, including a change of UK QPPV.

You do not need to update the initial information that was provided in the online form at the time of requesting your UK PSMF number (e.g. QPPV telephone number, MAHs covered by the pharmacovigilance system, etc.). This information is solely for the purpose of generating and allocating a unique UK PSMF number at a specific point in time. You must maintain the pharmacovigilance system information for your UK licences via the submission of the appropriate variations to the MHRA. Guidance on this process is provided below.

Guidance for applicants for UK marketing authorisations

The material to accompany an application for a UK marketing authorisation includes a summary of the applicant’s pharmacovigilance system (SPS).

This must include the following elements:

1. proof that the applicant has at their disposal an appropriately qualified person responsible for pharmacovigilance who resides and operates in the EU or the UK,
2. the country (which must be either the UK or a Member State) in which the appropriately qualified person resides and carries out his or her tasks
3. the contact details of the appropriately qualified person
4. a statement signed by the applicant which says that they have the necessary means to fulfil the tasks and responsibilities listed in Part 11
5. a reference to the location where the pharmacovigilance system master file for the medicinal product can be accessed electronically, which must be in the UK

The SPS should also include the UK PSMF number.

The above is following HMR Schedule 8.

Guidance on the application process and on registering to make submissions via the MHRA Submissions Portal is available.

You should use Agency Activity Reference ID: G0001 – Initial Marketing Authorisation Application and Subactivity Text: H002 – “Original Submission”.

Information on the QPPV and PSMF for UK authorised products should be entered in section 2.4.4 of the electronic application form (eAF). You should note the following:

• if the QPPV for UK authorised products resides and operates in the UK, the checkbox entitled “The above-mentioned qualified person resides and operates in the EEA” can remain unchecked.
• the UK location where the PSMF can be accessed from does not need to be registered in the Article 57 database, therefore the associated checkbox can remain unchecked.

For UK licence applications via mutual recognition or decentralised procedures, the UK SPS should be included in module 1.8.1 as a standalone file or alternatively under a UK subfolder.

Notification of QPPV and PSMF details to the MHRA by existing holders of UK marketing authorisations

ThisYou guidanceshould replacessubmit theType previousIAIN requirementvariations related to submitthe aSPS Typeto IA(IN)the variationMHRA and an accompanyingthese eCTDsubmissions sequenceshould tocover makeall theseUK changes.product Thislicences has(PL) beenunder simplifieda unique pharmacovigilance system.

How to make your submission

and

All onlyapplications anto update notificationthe isSPS required,are thererequired isto nobe requirementsubmitted toas submita anType eCTD sequence.IAIN This- guidanceC.I.8 appliesvariation fromvia 11the MayMHRA 2023

TheSubmissions summaryPortal. ofYou Pharmacovigilanceshould Systemuse (sPS)Agency isActivity aReference signedID: declarationG0098 by– bothVariation theType IA - Establishing UK QPPV -PSMF and theSubactivity MAH.Text: ItH002 contains– the“Original MAHSubmission”. detailsFor (i.e.UK Companylicences nameissued andvia address),mutual therecognition QPPV detailsor (i.e.decentralised QPPVprocedures, namea andvariation Contactto address),update the locationUK inSPS UKshould wherebe thesubmitted PSMFas cana be accessedUK-only National procedure and the UK PSMFSPS number.should Thebe eCTDincluded placein holdermodule for1.8.1 theas sPSa isstandalone modulefile 1.8.1.

Changesor havealternatively nowunder beena madeUK subfolder. Please refer to the wayOverview MHRAof shouldmanaging beupdates notified(PDF, of95.8 updatesKB, 1 page) to the QPPVSPS and PSMFfor detailsUK bylicences licenceissued holders.via mutual recognition or decentralised procedures.

ModuleWe 1.8.1are expecting a large volume of theregulatory eCTDsubmissions. productYou lifecycleshould willsubmit onlyyour needSPS updates as single changes and, to beprevent updateddelays, whenyou theshould PSMFsubmit is replacedin orcollections aof newno PSMFmore than 25 PLs.

You isshould registered.submit Theno registrationmore orthan replacementtwo ofcollections in a PSMFsingle willpackage still requireor within a newsingle UKweek PSMFwithout number.prior Allnotification.

You newmay Marketingcontact Authorisationthe applicationMHRA willat continueIPUScientificValidation@mhra.gov.uk to require discuss and agree the inclusionsubmission ofschedule aand sPSthe underprocessing moduletimelines. 1.8.1.Please Wheninclude reference ‘PSMFT1’ in the PSMFemail issubject replacedline.

Documentation becauseyou ofneed ato supply

change

You ofshould ownership,supply the newfollowing MAHdocumentation mustin include a copyC.I.8 ofsubmission the(Introduction newof, sPSor underchanges moduleto, 1.8.1 a summary of thepharmacovigilance COAsystem dossier.for Amedical Typeproducts IAfor C.I.8.ahuman variationuse):

• Proof willthat nothe longerapplicant behas requiredat whentheir disposal a newqualified PSMF isperson introducedresponsible orfor replacedpharmacovigilance becauseand of a Changestatement ofsigned Ownership.

  Theby followingthe changesapplicant to the sPSeffect willthat nothe longerapplicant requirehas the submissionnecessary ofmeans ato Typefulfil IA variationthe totasks updateand theresponsibilities sPSlisted butin canPart 11

• The country (which must be updatedeither viathe UK or a notificationMember update:
  • ChangesState) toin which the MAHappropriately detailsqualified (i.e.person Companyresides name and address)carries asout specifiedtheir in the sPStasks
  • TheContact QPPV details (i.e.of QPPVthe nameappropriately qualified person who resides and Contactoperates address)in the EU or the UK
  • TheA locationreference into UKthe location where the PSMF canfor bethe accessed.

  Tomedicinal makeproduct thesecan changes,be aaccessed, UKwhich onlymust sPSbe Updatein Notification, covering the affectedUK

• UK productPSMF number
licences

Failing (PL),to undersupply aall uniquerequired pharmacovigilancedocumentation system,and needsinformation may lead to bea submittedrejection toof the UKsubmission, to registerwhich thesewill changes.require Anyou updatedto eCTDmake sequencea isresubmission notaddressing required.all Therediscrepancies.

The isrequirements currentlyfor no feevarious forcategories sPSof Updatevariations Notifications.are Aoutlined Notificationin ofthe Acceptanceguidelines letterpublished willby bethe issuedCommission once finalisedunder onArticle our4 systems.of sPSRegulation Update(EC) notificationsNo will1234/2008.

Submission betimeframes

You processedmust withinnotify 30the daysMHRA of receipt of the application.

Howdetails toin makethe aSPS sPSfollowing Updateany Notification

Allchanges applications to update the sPSQPPV areresponsible requiredfor toUK beauthorised submittedproducts asfrom anthe sPSbaseline Update Notificationinformation viaheld by the MHRA. SubmissionsThe Portalbaseline immediatelyinformation soonis afterthe implementation: *QPPV Agencydetails Activitythat Referencewere IDregistered G0109:in SummaryeXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) at the end of Pharmacovigilance13 System UpdateDecember Notification2020. -For UK-any QPPV-PSMF * Subactivityupdates Text:submitted H002prior –to “Original13 Submission”December must2020, beyou selected. Youshould musthave submitreceived youra sPSsuccessful Updateacknowledgement Notificationsmessage outside(coded ofas the‘01’) eCTDindicating productthat lifecycle,the information in collections ofthe noXEVPRM morehas thanbeen 25processed PLssuccessfully. This is because the MHRA compiled andthe youQPPV shoulddetails submitfor noUK moreauthorised thanproducts onethat collectionwere in a singleXEVMPD package.

Documentationas youof need14 toDecember supply:

You2020. shouldChanges supplymade theafter following13 documentationDecember for2020 awill sPSnot Updatebe Notification:included in the baseline dataset.

1. Cover

   The lettersubmission (inof PDFSPS format)details detailingfor thelicences changesthat beingwere made.

2. sPS-Update-Notification-formauthorised (invia Excelthe format).EU Pleasecentralised downloadprocedure ashould copybe fromhandled here anddifferently completeto sectionsUK Anational andlicences. B.
3. ThePlease sPSrefer (into the Submission timeframe overview (PDF, format),12.3 whichKB, must1 includepage) thewhich followinghas information:

a.an Proofoverview thatof the applicanttimeframes hasfor atsubmitting theirSPS disposaldetails ato qualifiedthe personMHRA. responsibleFurther details for pharmacovigilance andthe adifferent statementlicence signedtypes byare theprovided applicantbelow.

Guidance relating to theUK effectnational that thelicences applicant(including hasthose theauthorised necessaryvia meansmutual torecognition fulfilor decentralised procedures)

If the tasksidentity, location and responsibilities listedcontact indetails Partof 11the HMRQPPV 2012.responsible Afor signedUK sPSauthorised byproducts bothare identical to that of the EU/EEA QPPV andat the MAHend of 13 December 2020 (as entered in XEVMPD will), suffice.no immediate action is required to notify the MHRA.

b.Within Thetwo countryweeks (whichof musta bechange eitherof identity, location or contact details of the QPPV responsible for UK orauthorised products, you should submit a Membersingle State)change inType whichIAIN the appropriately- qualifiedC.I.8 personvariation. forThis should cover all UK PLs under a unique pharmacovigilance residessystem and(in carriescollections out theirof tasks.no more than 25 PLs).

c.If Contactyou detailsanticipate ofno changes to the appropriatelyQPPV qualifieddetails personfrom forthose pharmacovigilance whoentered residesin andXEVMPD operatesby in30 theJune EU2022, orthen thethese UK.

d.details Afor referencethe toQPPV, together with the UK location wherethat the PSMF forcan thebe medicinalaccessed productfrom canand be accessed,UK whichPSMF mustnumber, should be insubmitted theas UK.a single change Type IAIN - C.I.8 variation by this deadline.

e.

Licences UKauthorised PSMFvia the EU number

centralised procedure

FailingAll toexisting supplyMAs allauthorised requiredthrough documentationthe andcentrally informationauthorised mayprocedure leadwill toautomatically abe rejectionconverted ofinto the notification,UK whichMAs. willThese requireMAs youwill tobe makeissued with a resubmissionUK addressingMA allnumber discrepancies.before the end of the transition period.

AYou notificationwill have a period of acceptanceone letteryear, willstarting beon issued1 whenJanuary we2021, haveto madesubmit the changesbaseline oninitiating our system.sequence data and related information in eCTD format.

PleaseAt notethe thatpoint anyof submission of the baseline initiating eCTD sequence submittedyou willshould befollow discardedthe asfollowing itguidance:

If isthe notidentity, requiredlocation asor part contact details of thisthe process.

Contact

GeneralQPPV queriesresponsible relatingfor UK authorised products are different to that of the EU/EEA QPPV, PSMFat andthe establishmentend of pharmacovigilance systems13 forDecember UK2020 authorised(as productsentered in XEVMPD), you should besimultaneously sentsubmit toa gpvpinspectors@mhra.gov.uk.

QueriesType relatingIAIN to- C.I.8 variation as a separate sequence in the UKsame PSMFsubmission numberpackage. shouldThis variation will be sentprocessed toonce UKPSMFadmin@mhra.gov.uk.the baseline sequence is processed.

QueriesIf relatingthe toidentity, submissionlocation and contact details of Typethe IAQPPV variationsresponsible shouldfor beUK sentauthorised products are identical to variationqueries@mhra.gov.uk

Forthat furtherof information,the pleaseEU/EEA emailQPPV ourat Customerthe Experienceend Centreof at13 info@mhra.gov.ukDecember or2020 call(as 020entered 3080in 6000.

YouXEVMPD), canno alsoimmediate emailaction vigilanceservice@mhra.gov.ukis withrequired urgentto questions.notify Alternatively,the contactMHRA. yourFollowing Trade Associationreceipt byof emailing:the baseline sequence approval letter from the MHRA, you should take the following actions:

• AssociationWithin two weeks of a change of identity, location or contact details of the BritishQPPV Pharmaceuticalresponsible Industryfor (ABPI):UK regulatory@abpi.org.uk
• Britishauthorised Genericproducts, Manufacturersyou Associationshould (BGMA):submit info@britishgenerics.co.uk
• BioIndustrya Associationsingle (BIA):change regulatory@bioindustry.org
• ClinicalType &IAIN Contract- ResearchC.I.8 Associationvariation. (CCRA):This mail@ccra.org.uk
• Ethicalshould Medicinescover Industryall GroupUK (EMIG):(ex-EU) info@emig.org.uk
• HealthPLs Foodunder Manufacturers’a Associationunique (HFMA):pharmacovigilance pennyviner@btconnect.com
• Thesystem National(in Pharmacycollections Associationof (NPA):no independentsvoice@npa.co.uk more than 25 PLs).
• ProprietaryIf Associationyou anticipate no changes to the QPPV details from those entered on XEVMPD by 30 June 2022, then the details of Greatthe BritainQPPV (PAGB):and regulatory@pagb.co.uk PSMF should be submitted by this deadline.

Notification of QPPV and PSMF details to XEVMPD

From 1 January 2021, for products in respect of Northern Ireland (UK-wide and Northern Ireland-only MAs), in addition to notifying the QPPV and PSMF details to the MHRA, you must submit information on the UK QPPV and the EU location of the UK PSMF to the Article 57 database in accordance with Regulation (EC) No 726/2004 Article 57(2).

Pharmacovigilance requirements for UK authorised products webinar recording, which took place on 13 January 2020. This webinar was part of a series of Brexit and post-transition guidance webinars:

Pharmacovigilance requirements for UK authorised products webinar recording, which took place on 13 January 2020:

Post transition: Pharmacovigilance requirements for UK authorised products webinar recording, which took place on 22 October 2020:

Pharmacovigilance requirements for UK authorised products webinar recording, which took place on 22 October 2020.

This webinar was part of a series of EU Exit and post-transition guidance webinars.

Contact

General queries relating to the QPPV, PSMF and establishment of pharmacovigilance systems for UK authorised products should be sent to gpvpinspectors@mhra.gov.uk

Queries relating to the UK PSMF number should be sent to UKPSMFadmin@mhra.gov.uk

Queries relating to submission of Type IA variations should be sent to variationqueries@mhra.gov.uk

For further information, please email our Customer Services Centre at info@mhra.gov.uk or call 020 3080 6000. You can also email vigilanceservice@mhra.gov.ukpharmacovigilanceservice@mhra.gov.uk with urgent questions. Alternatively, contact your Trade Association by emailing:

• Association of the British Pharmaceutical Industry (ABPI): regulatory@abpi.org.uk
• British Generic Manufacturers Association (BGMA): info@britishgenerics.co.uk
• BioIndustry Association (BIA): regulatory@bioindustry.org
• Clinical & Contract Research Association (CCRA): mail@ccra.org.uk
• Ethical Medicines Industry Group (EMIG): info@emig.org.uk
• Health Food Manufacturers’ Association (HFMA): pennyviner@btconnect.com
• The National Pharmacy Association (NPA): independentsvoice@npa.co.uk
• Proprietary Association of Great Britain (PAGB): regulatory@pagb.co.uk